Head and neck cancers in France: an analysis of the hospital medical information system PMSI databaseReport as inadecuate




Head and neck cancers in France: an analysis of the hospital medical information system PMSI database - Download this document for free, or read online. Document in PDF available to download.

Head and Neck Oncology

, 2:22

First Online: 01 September 2010Received: 20 July 2010Accepted: 01 September 2010

Abstract

BackgroundWith 16,005 new cases and 5,406 related deaths in 2005, France is particularly concerned by Head and Neck HandN cancers. In addition to tobacco and alcohol, Human Papillomavirus HPV has been reported as a risk factor for HandN cancers. The literature on the burden of these cancers in Europe is scarce. This study was performed to assess the medical and economical burden of hospitalisations for HandN cancers in France.

MethodsThe French national hospital database PMSI, in which admissions to public and private hospitals are recorded, was retrospectively analysed to assess the annual number of patients hospitalised for HandN cancers and associated hospital costs from the healthcare payer perspective. ICD-10 codes 16 codes classified as oral cavity, oropharynx, pharynx, salivary glands and larynx were used to extract admissions for these cancers. Hospital stays, chemotherapy and radiotherapy sessions were extracted to assess patients- management. Costs of admissions were obtained from French official tariffs.

ResultsIn 2007, there were 36 268 patients hospitalised for HandN cancers, of whom 81% were men, corresponding to 60 200 hospital stays and 287 846 sessions of chemo- or radio-therapy. Oropharynx cancer was the most frequent 28% of patients, followed by oral cavity cancer 25% of patients. The peak of frequency was observed in the 55-59 years age group. Patients were mainly treated in medicine 48% and surgery 23% units. Mean annual cost per patient ranged from €2 764 to €7 673 leading to a total hospital cost of €323 millions in 2007 including hospitalization and expensive drugs. With 26% of HandN cancers attributable to HPV infections, 9 430 patients were hospitalized due to HPV-related HandN cancers, representing €138 million in 2007.

ConclusionEven without taking into account the rehabilitation costs, the hospital burden of HandN cancers is considerable.

Electronic supplementary materialThe online version of this article doi:10.1186-1758-3284-2-22 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Jean Lacau St Guily - Isabelle Borget - Alexandre Vainchtock - Vanessa Rémy - Claire Takizawa

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents